RE: Ignore the Trolls. Hold 4 Gold23 Nov 2023 15:03
The £14m programme includes a range of projects in diagnosing liver disease, heart failure, lung cancer, chest pain and cardiometabolic conditions, as well as the ground-breaking DEVOTE programme, to deliver bedside genomic tests to prevent a second stroke in a patient who has experienced a stroke; rapid point of care devices to detect genetic changes; and the development of a ‘pharmacogenetic passport’ to improve the effectiveness and safety of medicines for patients.